In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. [PDF]
, 2010 BackgroundCruzain, the major cysteine protease of Trypanosoma cruzi, is an essential enzyme for the parasite life cycle and has been validated as a viable target to treat Chagas' disease.
Brinen, Linda S +6 more
core +44 more sources
Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile. [PDF]
, 2016 PurposeWe have established a prospective cohort of 1959 patients with chronic Chagas cardiomyopathy to evaluate if a clinical prediction rule based on ECG, brain natriuretic peptide (BNP) levels, and other biomarkers can be useful in clinical practice ...
Bierrenbach, Ana Luiza +10 more
core +3 more sources
Infectious Diseases of Poverty, 2021 Background Chagas disease is endemic in Latin America and, over the last few decades, due to population movements, the disease has spread to other continents. Early diagnosis and treatment are critical in terms of improving outcomes for those living with
María Romay-Barja +4 more
doaj +1 more source
Mortality among blood donors seropositive and seronegative for Chagas disease (1996-2000) in São Paulo, Brazil: A death certificate linkage study. [PDF]
PLoS Neglected Tropical Diseases, 2017 Individuals in the indeterminate phase of Chagas disease are considered to have mortality rates similar to those of the overall population. This study compares mortality rates among blood donors seropositive for Chagas disease and negative controls in ...
Ligia Capuani +7 more
doaj +1 more source
A protocol update for the Selenium Treatment and Chagasic Cardiomyopathy (STCC) trial
Trials, 2018 Several studies evaluating clinical forms of chronic Chagas disease show that about one-third of patients present cardiac involvement. Heart failure, sudden death and cardioembolic stroke are the main mechanisms of death in Chagas heart disease.
Marcelo Teixeira Holanda +24 more
doaj +1 more source
Troponin in Chagas disease [PDF]
Brazilian Journal of Infectious Diseases, 2003 Chagas disease is still a major tropical diseasein Latin America, affecting 16 to 18 million people.About 6 million people are infected with thecausative organism, Trypanosoma cruzi , in Brazil[1]. However, it often remains for decades in itsindeterminate form, symptomless, with tissue injuryin about 30% of the cases, which eventually willevolve to ...
Aras, Roque +6 more
openaire +6 more sources
Integrated control of chagas disease for its elimination as public health problem: A review [PDF]
, 2015 Chagas disease or American trypanosomiasis is, together with geohelminths, the neglected disease that causes more loss of years of healthy life due to disability in Latin America.
Segura, Elsa Leonor +1 more
core +4 more sources
Annals of Intensive Care, 2017 Background Early-onset ventilator-associated pneumonia (EO-VAP) is the leading cause of morbidity and mortality in comatose patients. However, VAP prevention bundles focus mainly on late-onset VAP and may be less effective in preventing EO-VAP in ...
Cássia Righy +4 more
doaj +1 more source
International meeting: New diagnostic tests are urgently needed to treat patients with Chagas disease. [PDF]
, 2008 Trypanosoma cruzi infection is often not detected early on or actively diagnosed, partly because most infected individuals are either asymptomatic or oligosymptomatic.
Campaign for Access to Essential Medicines
core +3 more sources
Congenital Chagas Disease in the United States: Cost Savings Through Maternal Screening [PDF]
, 2018 Chagas disease, caused by Trypanosoma cruzi, is transmitted by insect vectors through transfusions, transplants, insect feces in food, and from mother to child during gestation.
Bialek, Stephanie R. +3 more
core +2 more sources